{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:52:07Z","timestamp":1785840727200,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273350"],"award-info":[{"award-number":["82273350"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370777"],"award-info":[{"award-number":["82370777"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"The Beijing Natural Science Foundation","award":["L248054"],"award-info":[{"award-number":["L248054"]}]},{"name":"The National High Level Hospital Clinical Research Funding","award":["2023IR04"],"award-info":[{"award-number":["2023IR04"]}]},{"name":"The Wuxi \"Taihu Talents Program\" Medical and Health High-level Talents Project","award":["NA."],"award-info":[{"award-number":["NA."]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bladder cancer (BC) presents a major clinical challenge due to high recurrence and progression rates, highlighting the need for novel therapeutic targets. While the N6-methyladenosine (m6A) writer complex is broadly implicated, the specific function and regulatory mechanism of its adaptor protein RNA binding motif protein 15 (RBM15) remain poorly defined in BC. This study reveals the oncogenic role of RBM15 in BC and its m6A-dependent regulatory axis, providing a new rationale for targeted intervention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The clinical relevance of RBM15 was established by assessing its expression and prognostic significance in public datasets and a large clinical cohort. The biological function of RBM15 and its effect on global m6A methylation were subsequently investigated using a comprehensive suite of in vitro assays and in vivo models. We performed integrated multiomics analyses (RNA-seq, m6A-seq, and RIP-seq) and validated the underlying molecular mechanisms by performing additional targeted assays to elucidate the downstream regulatory network. Finally, the therapeutic potential of targeting this axis was validated in preclinical models using the METTL3 catalytic inhibitor STM2457.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RBM15 was significantly upregulated in BC, and its elevated expression served as an independent predictor of a poor prognosis. Functionally, RBM15 increased global m6A levels and promoted the malignant progression of BC cells both in vitro and in vivo; these oncogenic effects were reversed upon RBM15 knockdown. Mechanistically, RBM15 bound Zona Occludens 2 (ZO2) mRNA and recruited the methyltransferase 3\u2013methyltransferase 14\u2013Wilms\u2019 tumor 1-associating protein (METTL3-METTL14-WTAP) methyltransferase complex to increase the level of the m6A modification on the ZO2 mRNA. This modification was recognized by YTH N(6)-methyladenosine RNA binding protein 2 (YTHDF2) to accelerate ZO2 mRNA decay. Although ZO2 expression was globally reduced, its preferential nuclear accumulation was increased, which promoted Snail expression and accelerated malignant progression. The METTL3 catalytic inhibitor STM2457 suppressed BC growth and lung metastasis by targeting the METTL3\/RBM15\/ZO2 axis, with no observable toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>RBM15 acts as an oncogenic driver in BC by facilitating the m6A-dependent degradation of ZO2 mRNA via the recruitment of the METTL3 complex and recognition by YTHDF2. Targeting this METTL3\/RBM15\/ZO2 axis with STM2457 represents a promising therapeutic strategy for BC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03684-9","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T05:44:58Z","timestamp":1774849498000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["RBM15 drives bladder cancer progression through YTHDF2-dependent m6A-mediated regulation of ZO2"],"prefix":"10.1186","volume":"45","author":[{"given":"Yuhui","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqing","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenduo","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conghui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuesong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"3684_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3684_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero P, Birtle A, Capoun O, Comp\u00e9rat E, Dominguez-Escrig JL, Liedberg F, et al. European association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update. Eur Urol. 2024;86:531\u201349.","journal-title":"Eur Urol"},{"key":"3684_CR3","doi-asserted-by":"crossref","unstructured":"Sylvester RJ, van der Meijden APM, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466\u201377.","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"3684_CR4","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.eururo.2011.07.065","volume":"60","author":"BJ Schmitz-Dr\u00e4ger","year":"2011","unstructured":"Schmitz-Dr\u00e4ger BJ. Identifying risk factors in patients with non\u2013muscle-invasive bladder cancer: clinical implications. Eur Urol. 2011;60:721\u201323.","journal-title":"Eur Urol"},{"key":"3684_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1111\/bju.14872","volume":"125","author":"A Martini","year":"2020","unstructured":"Martini A, Sfakianos JP, Renstr\u00f6m-Koskela L, Mortezavi A, Falagario UG, Egevad L, et al. The natural history of untreated muscle\u2010invasive bladder cancer. BJU Int. 2020;125:270\u201375.","journal-title":"BJU Int"},{"key":"3684_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.eururo.2011.05.035","volume":"60","author":"A Fleischmann","year":"2011","unstructured":"Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol. 2011;60:350\u201357.","journal-title":"Eur Urol"},{"key":"3684_CR7","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cac2.12602","volume":"44","author":"M Noeraparast","year":"2024","unstructured":"Noeraparast M, Krajina K, Pichler R, Nieders\u00fc\u00df-Beke D, Shariat SF, Gr\u00fcnwald V, et al. FGFR3 alterations in bladder cancer: sensitivity and resistance to targeted therapies. Cancer Commun (Lond). 2024;44:1189\u2013208.","journal-title":"Cancer Commun (Lond)"},{"key":"3684_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/s41585-023-00851-x","volume":"21","author":"L Yang","year":"2024","unstructured":"Yang L, Ying J, Tao Q, Zhang Q. RNA N6-methyladenosine modifications in urological cancers: from mechanism to application. Nat Rev Urol. 2024;21:460\u201376.","journal-title":"Nat Rev Urol"},{"key":"3684_CR9","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1038\/s41571-023-00774-x","volume":"20","author":"X Deng","year":"2023","unstructured":"Deng X, Qing Y, Horne D, Huang H, Chen J. The roles and implications of RNA m6A modification in cancer. Nat Rev Clin Oncol. 2023;20:507\u201326.","journal-title":"Nat Rev Clin Oncol"},{"key":"3684_CR10","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1038\/s41388-019-0683-z","volume":"38","author":"M Cheng","year":"2019","unstructured":"Cheng M, Sheng L, Gao Q, Xiong Q, Zhang H, Wu M, et al. The m6A methyltransferase METTL3 promotes bladder cancer progression via AFF4\/NF-\u03baB\/MYC signaling network. Oncogene. 2019;38:3667\u201380.","journal-title":"Oncogene"},{"key":"3684_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12943-019-1036-9","volume":"18","author":"J Han","year":"2019","unstructured":"Han J, Wang J-Z, Yang X, Yu H, Zhou R, Lu H-C, et al. METTL3 promote tumor proliferation of bladder cancer by accelerating pri-miR221\/222 maturation in m6A-dependent manner. Mol Cancer. 2019;18:110.","journal-title":"Mol Cancer"},{"key":"3684_CR12","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1158\/0008-5472.CAN-21-1323","volume":"82","author":"Z Ni","year":"2022","unstructured":"Ni Z, Sun P, Zheng J, Wu M, Yang C, Cheng M, et al. JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6a modification of PD-L1 mRNA. Cancer Res. 2022;82:1789\u2013802.","journal-title":"Cancer Res"},{"key":"3684_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13046-021-01871-4","volume":"40","author":"X Wang","year":"2021","unstructured":"Wang X, Tian L, Li Y, Wang J, Yan B, Yang L, et al. RBM15 facilitates laryngeal squamous cell carcinoma progression by regulating TMBIM6 stability through IGF2BP3 dependent. J Exp Clin Cancer Res. 2021;40:80.","journal-title":"J Exp Clin Cancer Res"},{"key":"3684_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41420-021-00703-w","volume":"7","author":"X Cai","year":"2021","unstructured":"Cai X, Chen Y, Man D, Yang B, Feng X, Zhang D, et al. RBM15 promotes hepatocellular carcinoma progression by regulating N6-methyladenosine modification of YES1 mRNA in an IGF2BP1-dependent manner. Cell Death Discov. 2021;7:315.","journal-title":"Cell Death Discov"},{"key":"3684_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/ng.2764","volume":"45","author":"JN Weinstein","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113\u201320.","journal-title":"Nat Genet"},{"key":"3684_CR16","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.aaz1776","volume":"369","author":"GTEx Consortium","year":"2020","unstructured":"GTEx Consortium. The GTEx consortium atlas of genetic regulatory effects across human tissues. Science. 2020;369:1318\u201330.","journal-title":"Science"},{"key":"3684_CR17","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","volume":"47","author":"Z Tang","year":"2019","unstructured":"Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47:W556\u201360.","journal-title":"Nucleic Acids Res"},{"key":"3684_CR18","doi-asserted-by":"publisher","first-page":"bbaa055","DOI":"10.1093\/bib\/bbaa055","volume":"22","author":"S Deng","year":"2021","unstructured":"Deng S, Zhang H, Zhu K, Li X, Ye Y, Li R, et al. M6A2Target: a comprehensive database for targets of m6A writers, erasers and readers. Brief Bioinform. 2021;22:bbaa055.","journal-title":"Brief Bioinform"},{"key":"3684_CR19","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s13577-021-00661-6","volume":"35","author":"Y Wu","year":"2022","unstructured":"Wu Y, Zhang C, Peng D, He S, Huang C, Qian J, et al. MiR-182-5p inhibits the tumorigenesis of clear cell renal cell carcinoma by repressing UBE2T. Hum Cell. 2022;35:542\u201356.","journal-title":"Hum Cell"},{"key":"3684_CR20","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.humpath.2014.07.003","volume":"45","author":"SF Faraj","year":"2014","unstructured":"Faraj SF, Chaux A, Gonzalez-Roibon N, Munari E, Ellis C, Driscoll T, et al. ARID1A immunohistochemistry improves outcome prediction in invasive urothelial carcinoma of urinary bladder. Hum Pathol. 2014;45:2233\u201339.","journal-title":"Hum Pathol"},{"key":"3684_CR21","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.3390\/ijms24108801","volume":"24","author":"HS Kim","year":"2023","unstructured":"Kim HS, Lee SI, Choi YR, Kim J, Eun JW, Song KS, et al. GNAQ-Regulated ZO-1 and ZO-2 Act as Tumor Suppressors by Modulating EMT Potential and Tumor-Repressive Microenvironment in Lung Cancer. Int J Mol Sci. 2023;24:8801.","journal-title":"Int J Mol Sci"},{"key":"3684_CR22","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tig.2019.12.007","volume":"36","author":"Y Lee","year":"2020","unstructured":"Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m6A modification. Trends Genet. 2020;36:177\u201388.","journal-title":"Trends Genet"},{"key":"3684_CR23","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1074\/jbc.M206821200","volume":"278","author":"A Traweger","year":"2003","unstructured":"Traweger A, Fuchs R, Krizbai IA, Weiger TM, Bauer H-C, Bauer H. The tight junction protein ZO-2 localizes to the nucleus and interacts with the heterogeneous nuclear ribonucleoprotein Scaffold attachment factor-B. J Biol Chem. 2003;278:2692\u2013700.","journal-title":"J Biol Chem"},{"key":"3684_CR24","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, Lu Z, Gomez A, Hon GC, Yue Y, Han D, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505:117\u201320.","journal-title":"Nature"},{"key":"3684_CR25","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1038\/cr.2014.153","volume":"24","author":"F Li","year":"2014","unstructured":"Li F, Zhao D, Wu J, Shi Y. Structure of the YTH domain of human YTHDF2 in complex with an m6A mononucleotide reveals an aromatic cage for m6A recognition. Cell Res. 2014;24:1490\u201392.","journal-title":"Cell Res"},{"key":"3684_CR26","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-019-1374-1","volume":"571","author":"RJ Ries","year":"2019","unstructured":"Ries RJ, Zaccara S, Klein P, Olarerin-George A, Namkoong S, Pickering BF, et al. m6A enhances the phase separation potential of mRNA. Nature. 2019;571:424\u201328.","journal-title":"Nature"},{"key":"3684_CR27","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1038\/cr.2014.152","volume":"24","author":"T Zhu","year":"2014","unstructured":"Zhu T, Roundtree IA, Wang P, Wang X, Wang L, Sun C, et al. Crystal structure of the YTH domain of YTHDF2 reveals mechanism for recognition of N6-methyladenosine. Cell Res. 2014;24:1493\u201396.","journal-title":"Cell Res"},{"key":"3684_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","volume":"593","author":"E Yankova","year":"2021","unstructured":"Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593:597\u2013601.","journal-title":"Nature"},{"key":"3684_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/nature18298","volume":"534","author":"X Wang","year":"2016","unstructured":"Wang X, Feng J, Xue Y, Guan Z, Zhang D, Liu Z, et al. Structural basis of N6-adenosine methylation by the METTL3\u2013METTL14 complex. Nature. 2016;534:575\u201378.","journal-title":"Nature"},{"key":"3684_CR30","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.molcel.2016.03.021","volume":"62","author":"S Lin","year":"2016","unstructured":"Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m6A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62:335\u201345.","journal-title":"Mol Cell"},{"key":"3684_CR31","first-page":"0970","volume":"8","author":"J Sun","year":"2025","unstructured":"Sun J, Shi Y, Yu K, Huang S, Lu D, Niu X, et al. Hypoxia-induced histone lactylation drives cisplatin resistance in bladder cancer by promoting RBM15-dependent m6A methylation of IGFBP3. Res (Wash D C). 2025;8:0970.","journal-title":"Res (Wash D C)"},{"key":"3684_CR32","doi-asserted-by":"publisher","first-page":"e28165","DOI":"10.1016\/j.heliyon.2024.e28165","volume":"10","author":"Y Huang","year":"2024","unstructured":"Huang Y, Lv Y, Yang B, Zhang S, Bixia L, Zhang C, et al. Enhancing m6A modification of lncRNA through METTL3 and RBM15 to promote malignant progression in bladder cancer. Heliyon. 2024;10:e28165.","journal-title":"Heliyon"},{"key":"3684_CR33","doi-asserted-by":"publisher","first-page":"4128","DOI":"10.3390\/ijms20174128","volume":"20","author":"L Gonz\u00e1lez-Mariscal","year":"2019","unstructured":"Gonz\u00e1lez-Mariscal L, Gallego-Guti\u00e9rrez H, Gonz\u00e1lez-Gonz\u00e1lez L, Hern\u00e1ndez-Guzm\u00e1n C. ZO-2 is a master regulator of gene expression, cell proliferation, cytoarchitecture, and cell size. Int J Mol Sci. 2019;20:4128.","journal-title":"Int J Mol Sci"},{"key":"3684_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3390\/cells12020243","volume":"12","author":"Z Nehme","year":"2023","unstructured":"Nehme Z, Roehlen N, Dhawan P, Baumert TF. Tight junction protein signaling and cancer biology. Cells. 2023;12:243.","journal-title":"Cells"},{"key":"3684_CR35","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","volume":"15","author":"Y Huang","year":"2022","unstructured":"Huang Y, Hong W, Wei X. The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis. J Hematol Oncol. 2022;15:129.","journal-title":"J Hematol Oncol"},{"key":"3684_CR36","doi-asserted-by":"publisher","first-page":"e3002487","DOI":"10.1371\/journal.pbio.3002487","volume":"22","author":"T Celi\u00e0-Terrassa","year":"2024","unstructured":"Celi\u00e0-Terrassa T, Kang Y. How important is EMT for cancer metastasis? PLoS Biol. 2024;22:e3002487.","journal-title":"PLoS Biol"},{"key":"3684_CR37","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.canlet.2019.10.013","volume":"468","author":"Y Jiang","year":"2020","unstructured":"Jiang Y, Zhan H. Communication between EMT and PD-L1 signaling: new insights into tumor immune evasion. Cancer Lett. 2020;468:72\u201381.","journal-title":"Cancer Lett"},{"key":"3684_CR38","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1007\/s10238-023-01229-4","volume":"23","author":"SO Imodoye","year":"2023","unstructured":"Imodoye SO, Adedokun KA. EMT-induced immune evasion: connecting the dots from mechanisms to therapy. Clin Exp Med. 2023;23:4265\u201387.","journal-title":"Clin Exp Med"},{"key":"3684_CR39","doi-asserted-by":"crossref","unstructured":"Yu H, Liu J, Bu X, Ma Z, Yao Y, Li J, et al. Targeting METTL3 reprograms the tumor microenvironment to improve cancer immunotherapy. Cell Chem Biol. 2024;31:776\u201391.","DOI":"10.1016\/j.chembiol.2023.09.001"},{"key":"3684_CR40","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1158\/2326-6066.CIR-24-1179","volume":"13","author":"M Fang","year":"2025","unstructured":"Fang M, Li Y, Wang P, Wang Y, Wang X, Wa X, et al. METTL3 inhibition restores PD-L1 expression and CD8\u2009+\u2009T-cell cytotoxic function in immunotherapy-treated gastric cancer. Cancer Immunol Res. 2025;13:1037\u201352.","journal-title":"Cancer Immunol Res"},{"key":"3684_CR41","doi-asserted-by":"publisher","first-page":"e70089","DOI":"10.1002\/ctm2.70089","volume":"14","author":"K Wu","year":"2024","unstructured":"Wu K, Li S, Hong G, Dong H, Tang T, Liu H, et al. Targeting METTL3 as a checkpoint to enhance T cells for tumour immunotherapy. Clin Transl Med. 2024;14:e70089.","journal-title":"Clin Transl Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03684-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03684-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:07:25Z","timestamp":1781644045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03684-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3684"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03684-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"10 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Peking University First Hospital (Approval No. 2025R0010-0002 and No. 2022-279-002), and written informed consent was obtained from all participants.All animal procedures were approved by the Peking University First Hospital Animal Ethics Committee (J2021115) and conducted in strict accordance with the 3R principles (replacement, reduction, and refinement).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was obtained from all the authors of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}